These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 38521968)
1. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968 [TBL] [Abstract][Full Text] [Related]
2. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Henderson YC; Fredrick MJ; Clayman GL Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622 [TBL] [Abstract][Full Text] [Related]
3. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859 [TBL] [Abstract][Full Text] [Related]
4. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Hicks HM; McKenna LR; Espinoza VL; Pozdeyev N; Pike LA; Sams SB; LaBarbera D; Reigan P; Raeburn CD; E Schweppe R Mol Carcinog; 2021 Mar; 60(3):201-212. PubMed ID: 33595872 [TBL] [Abstract][Full Text] [Related]
6. Combination Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898 [No Abstract] [Full Text] [Related]
7. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538 [TBL] [Abstract][Full Text] [Related]
8. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251 [TBL] [Abstract][Full Text] [Related]
9. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
10. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021 [TBL] [Abstract][Full Text] [Related]
11. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. Xu M; Casio M; Range DE; Sosa JA; Counter CM Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097 [No Abstract] [Full Text] [Related]
12. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
13. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
15. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Cronise KE; Hernandez BG; Gustafson DL; Duval DL Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548 [TBL] [Abstract][Full Text] [Related]
16. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
17. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312 [TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Parker R; Clifton-Bligh R; Molloy MP Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855 [TBL] [Abstract][Full Text] [Related]
19. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431 [TBL] [Abstract][Full Text] [Related]
20. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Kessler BE; Mishall KM; Kellett MD; Clark EG; Pugazhenthi U; Pozdeyev N; Kim J; Tan AC; Schweppe RE Oncogene; 2019 Apr; 38(14):2565-2579. PubMed ID: 30531837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]